The finding that the drug also decreases beta cell apoptosis in islets from patients with T2DM, and improves their insulin secretion as well as improves beta cell survival in xenotransplantation, opens the exciting perspective that it could be of value also in the human clinic. This evidence concerns the gene INS and type 2 diabetes mellitus.